Neuromodulation Market by Technology (Internal, External), Stimulation Type (Spinal Cord, Deep Brain, Vagus Nerve Stimulation), Application (Ischemia, Depression, Epilepsy, Obesity), End User (Hospitals, ASCs, Clinics) & Region - Global Forecast to 2030
Description
The global neuromodulation market is projected to reach USD 10.68 billion by 2030 from USD 6.81 billion in 2025, at a CAGR of 9.4% during the forecast period.
The neuromodulation market is expanding due to the rising prevalence of neurological disorders, the development of new neuromodulation technologies, and the increasing geriatric population, all of which contribute to market growth. Additionally, the high cost of neuromodulation procedures may limit the market growth.
“The hospitals & ambulatory surgery centers segment of the neuromodulation end user market is expected to hold the largest position during the forecast period.”
By end user, it is segmented into hospitals & ambulatory surgery centers, clinics & physiotherapy centers, and other end users. In 2024, hospitals & ambulatory surgery centers will hold the largest market share. The hospitals and ambulatory care segment dominates the neuromodulation market due to its ability to provide comprehensive, multidisciplinary care and access to advanced neuromodulation therapies. These settings are equipped with specialized surgical facilities, trained clinicians, and monitoring systems necessary for implantable and complex neuromodulation procedures. Hospitals and ambulatory centers also benefit from established reimbursement frameworks, making costly procedures more accessible to patients. Moreover, the increasing focus on chronic disease management, postoperative care, and patient follow-up is driving high procedure volumes in these settings, reinforcing their leadership in neuromodulation delivery solutions.
“The internal neuromodulation accounted for the largest market share in the neuromodulation market.”
The neuromodulation technology market is segmented into internal neuromodulation and external neuromodulation. The internal neuromodulation segment accounted for the largest share in the neuromodulation market in 2024. Internal neuromodulation has become the dominant approach in the market due to its sophisticated technology that facilitates targeted stimulation of specific neural pathways. This process is instrumental in the chronic management of conditions such as nociceptive pain, Parkinson's disease, and urinary or fecal incontinence. The implantable devices are characterized by features like rechargeable or long-lasting batteries, customizable stimulation protocols, closed-loop feedback mechanisms, and wireless connectivity. These capabilities enable real-time monitoring and tailored therapeutic adjustments to enhance patient outcomes. The technological advancements support compact device designs that minimize invasiveness, thereby improving patient comfort and adherence to treatment. Furthermore, ongoing innovation in materials science, electrode architecture, and software algorithms continues to improve the efficacy, safety, and longevity of these systems. As a result, internal neuromodulation is increasingly favored over non-invasive interventions in clinical practice.
“The Asia Pacific is the fastest-growing region of the neuromodulation market by region.”
The global neuromodulation market is divided into five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is the fastest-growing area in the neuromodulation market due to increasing health awareness, a rising rate of neurological and chronic pain disorders, and expanding healthcare infrastructure in countries like China, India, and Japan. The region is seeing greater adoption of advanced neuromodulation technologies, helped by better reimbursement policies and government efforts to improve access to medical devices. Additionally, a large patient population, higher disposable incomes, and increased investments from both global and local device manufacturers are fueling market growth. The push to establish specialized treatment centers and the gradual adoption of minimally invasive and implantable products further boost neuromodulation use in the region. Moreover, the rise in medical tourism in countries such as India, Thailand, and Singapore is increasing surgical volumes, which in turn raises the demand for post-operative care and neuromodulation.
A breakdown of the primary participants referred to for this report is provided below:
Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.
Note 3: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
The major players operating in the neuromodulation market are Medtronic (US), Boston Scientific Corporation (US), Abbott (US), LivaNova PLC (UK), Nevro Corp (US), NeuroPace, Inc. (US), Bioventus (US), electroCore, Inc. (US), Helius Medical Technologies, Inc. (US), and Neuronetics (US).
Research Coverage
This report examines the neuromodulation market based on technology, stimulation type, application, end user, and country. It also analyzes factors such as drivers, restraints, opportunities, and challenges that influence market growth, along with details of the competitive landscape for market leaders. Additionally, the report studies micro markets according to their individual growth trends. It forecasts the revenue of market segments across five major regions and their respective countries.
Reasons to Buy the Report
The report will help both established and smaller firms to understand market trends, which, in turn, will assist them in gaining a larger market share. Companies purchasing the report can use one or a combination of the strategies listed below to strengthen their market position.
This report provides insights into the following pointers:
The neuromodulation market is expanding due to the rising prevalence of neurological disorders, the development of new neuromodulation technologies, and the increasing geriatric population, all of which contribute to market growth. Additionally, the high cost of neuromodulation procedures may limit the market growth.
“The hospitals & ambulatory surgery centers segment of the neuromodulation end user market is expected to hold the largest position during the forecast period.”
By end user, it is segmented into hospitals & ambulatory surgery centers, clinics & physiotherapy centers, and other end users. In 2024, hospitals & ambulatory surgery centers will hold the largest market share. The hospitals and ambulatory care segment dominates the neuromodulation market due to its ability to provide comprehensive, multidisciplinary care and access to advanced neuromodulation therapies. These settings are equipped with specialized surgical facilities, trained clinicians, and monitoring systems necessary for implantable and complex neuromodulation procedures. Hospitals and ambulatory centers also benefit from established reimbursement frameworks, making costly procedures more accessible to patients. Moreover, the increasing focus on chronic disease management, postoperative care, and patient follow-up is driving high procedure volumes in these settings, reinforcing their leadership in neuromodulation delivery solutions.
“The internal neuromodulation accounted for the largest market share in the neuromodulation market.”
The neuromodulation technology market is segmented into internal neuromodulation and external neuromodulation. The internal neuromodulation segment accounted for the largest share in the neuromodulation market in 2024. Internal neuromodulation has become the dominant approach in the market due to its sophisticated technology that facilitates targeted stimulation of specific neural pathways. This process is instrumental in the chronic management of conditions such as nociceptive pain, Parkinson's disease, and urinary or fecal incontinence. The implantable devices are characterized by features like rechargeable or long-lasting batteries, customizable stimulation protocols, closed-loop feedback mechanisms, and wireless connectivity. These capabilities enable real-time monitoring and tailored therapeutic adjustments to enhance patient outcomes. The technological advancements support compact device designs that minimize invasiveness, thereby improving patient comfort and adherence to treatment. Furthermore, ongoing innovation in materials science, electrode architecture, and software algorithms continues to improve the efficacy, safety, and longevity of these systems. As a result, internal neuromodulation is increasingly favored over non-invasive interventions in clinical practice.
“The Asia Pacific is the fastest-growing region of the neuromodulation market by region.”
The global neuromodulation market is divided into five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is the fastest-growing area in the neuromodulation market due to increasing health awareness, a rising rate of neurological and chronic pain disorders, and expanding healthcare infrastructure in countries like China, India, and Japan. The region is seeing greater adoption of advanced neuromodulation technologies, helped by better reimbursement policies and government efforts to improve access to medical devices. Additionally, a large patient population, higher disposable incomes, and increased investments from both global and local device manufacturers are fueling market growth. The push to establish specialized treatment centers and the gradual adoption of minimally invasive and implantable products further boost neuromodulation use in the region. Moreover, the rise in medical tourism in countries such as India, Thailand, and Singapore is increasing surgical volumes, which in turn raises the demand for post-operative care and neuromodulation.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1: 28%, Tier 2: 42%, and Tier 3: 30%
- By Designation: C Level: 30%, Director Level: 34%, and Others: 36%
- By Region: North America: 51%, Europe: 21%, Asia Pacific: 18%, Latin America: 6%, and Middle East & Africa: 4%
Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.
Note 3: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
The major players operating in the neuromodulation market are Medtronic (US), Boston Scientific Corporation (US), Abbott (US), LivaNova PLC (UK), Nevro Corp (US), NeuroPace, Inc. (US), Bioventus (US), electroCore, Inc. (US), Helius Medical Technologies, Inc. (US), and Neuronetics (US).
Research Coverage
This report examines the neuromodulation market based on technology, stimulation type, application, end user, and country. It also analyzes factors such as drivers, restraints, opportunities, and challenges that influence market growth, along with details of the competitive landscape for market leaders. Additionally, the report studies micro markets according to their individual growth trends. It forecasts the revenue of market segments across five major regions and their respective countries.
Reasons to Buy the Report
The report will help both established and smaller firms to understand market trends, which, in turn, will assist them in gaining a larger market share. Companies purchasing the report can use one or a combination of the strategies listed below to strengthen their market position.
This report provides insights into the following pointers:
- Analysis of key drivers (rising prevalence of neurological disorders and nerve injuries, rising geriatric population and subsequent growth in prevalence of neurological disorders, rising government support and funding for neurological disorders, increasing focus on development of advanced neuromodulation and neurostimulation technologies, increasing collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices, and availability of reimbursements for neuromodulation devices), restraints (high cost of neuromodulation procedures, preference for drug therapies over neuromodulation products, and adverse effects and complications associated with neuromodulation devices), opportunities (large population and increasing healthcare expenditure in emerging economies, and widening application scope of neuromodulation), challenges (stringent regulatory framework and time-consuming approval processes for neuromodulation and neurostimulation devices, and shortage of trained professionals)
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the neuromodulation market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the neuromodulation market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the neuromodulation market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players
Table of Contents
367 Pages
- 1 Introduction
- 1.1 Study Objectives
- 1.2 Market Definition
- 1.3 Study Scope
- 1.3.1 Market Segmentation & Regional Scope
- 1.3.2 Inclusions & Exclusions
- 1.3.3 Years Considered
- 1.3.4 Currency Considered
- 1.4 Stakeholders
- 1.5 Summary Of Changes
- 2 Research Methodology
- 2.1 Research Data
- 2.1.1 Secondary Data
- 2.1.1.1 List Of Key Secondary Sources
- 2.1.1.2 Key Data From Secondary Sources
- 2.1.2 Primary Data
- 2.1.2.1 Key Objectives Of Primary Research
- 2.1.2.2 List Of Primary Sources
- 2.1.2.3 Key Data From Primary Sources
- 2.1.2.4 Breakdown Of Primary Interviews
- 2.1.2.5 Insights From Industry Experts
- 2.2 Market Size Estimation
- 2.2.1 Bottom-up Approach
- 2.2.1.1 Revenue Estimation Of Key Players
- 2.2.1.2 Study Of Annual Reports And Investor Presentations
- 2.2.1.3 Primary Interviews
- 2.2.1.4 Growth Forecast
- 2.2.1.5 Cagr Projections
- 2.2.2 Top-down Approach
- 2.3 Data Triangulation
- 2.4 Study Assumptions
- 2.4.1 Research-related Assumptions
- 2.4.2 Parametric Assumptions
- 2.4.3 Growth-rate Assumptions
- 2.4.4 Market Assumptions
- 2.5 Research Limitations
- 2.6 Risk Analysis
- 3 Executive Summary
- 4 Premium Insights
- 4.1 Attractive Opportunities For Players In Neuromodulation Market
- 4.2 Asia Pacific: Neuromodulation Market, By End User And Country, 2024
- 4.3 Neuromodulation Market: Geographical Growth Opportunities
- 4.4 Neuromodulation Market: Regional Mix
- 5 Market Overview
- 5.1 Introduction
- 5.2 Market Dynamics
- 5.2.1 Drivers
- 5.2.1.1 Rising Prevalence Of Neurological Disorders And Nerve Injuries
- 5.2.1.2 High Incidence Of Neurological Disorders Among Geriatric Population
- 5.2.1.3 Favorable Government Support And Funding With Advanced Healthcare Infrastructure
- 5.2.1.4 Development Of Advanced Neuromodulation And Neurostimulation Technologies
- 5.2.1.5 Growing Collaborations Among Device Manufacturers, Healthcare Providers, And Research Institutions
- 5.2.1.6 Availability Of Reimbursements For Neuromodulation Devices
- 5.2.2 Restraints
- 5.2.2.1 High Cost Of Neuromodulation Procedures
- 5.2.2.2 Preference For Drug Therapies Over Neuromodulation Products
- 5.2.2.3 Adverse Effects And Complications With Neuromodulation Devices
- 5.2.3 Opportunities
- 5.2.3.1 Large Population And High Healthcare Expenditure In Emerging Economies
- 5.2.3.2 Widening Application Scope Of Neuromodulation
- 5.2.4 Challenges
- 5.2.4.1 Stringent Regulatory Framework And Time-consuming Approval Processes For Neuromodulation And Neurostimulation Devices
- 5.2.4.2 Shortage Of Trained Professionals
- 5.3 Trends/Disruptions Impacting Customer’s Business
- 5.4 Pricing Analysis
- 5.4.1 Average Selling Price Trend Of Neuromodulation Products,
- By Stimulation Type, 2023–2025
- 5.4.2 Average Selling Price Trend Of Neuromodulation Products,
- By Key Player, 2023–2025
- 5.4.3 Average Selling Price Trend Of Neuromodulation Products,
- By Region, 2023–2025
- 5.5 Value Chain Analysis
- 5.6 Supply Chain Analysis
- 5.7 Ecosystem Analysis
- 5.8 Investment & Funding Scenario
- 5.9 Technology Analysis
- 5.9.1 Key Technologies
- 5.9.1.1 Transcutaneous Electrical Nerve Stimulation
- 5.9.2 Complementary Technologies
- 5.9.2.1 Wearable Biosensors
- 5.9.3 Adjacent Technologies
- 5.9.3.1 Regenerative Medicine And Stem Cells
- 5.10 Patent Analysis
- 5.10.1 List Of Key Patents
- 5.11 Trade Data Analysis
- 5.11.1 Import Data For Hs Code 901890
- 5.11.2 Export Data For Hs Code 901890
- 5.12 Key Conferences & Events, 2025–2026
- 5.13 Case Study Analysis
- 5.13.1 Use Of Neuralmodulation Technologies In Research,
- Clinical Practice, And Consumer Applications
- 5.13.2 Pairing Translingual Neurostimulation With Intensive Rehabilitation To Enhance Neuroplasticity And Improve Motor Recovery In Severe Traumatic Brain Injury Patients
- 5.13.3 Application Of Neuromodulation Techniques—from Non-invasive Brain Stimulation To Deep Brain Stimulation
- 5.14 Regulatory Analysis
- 5.14.1 Regulatory Landscape
- 5.14.1.1 North America
- 5.14.1.1.1 Us
- 5.14.1.1.2 Canada
- 5.14.1.2 Europe
- 5.14.1.3 Asia Pacific
- 5.14.1.3.1 China
- 5.14.1.3.2 Japan
- 5.14.1.3.3 India
- 5.14.2 Regulatory Bodies, Government Agencies, And Other Organizations
- 5.15 Porter’s Five Forces Analysis
- 5.15.1 Bargaining Power Of Suppliers
- 5.15.2 Bargaining Power Of Buyers
- 5.15.3 Threat Of New Entrants
- 5.15.4 Threat Of Substitutes
- 5.15.5 Intensity Of Competitive Rivalry
- 5.16 Key Stakeholders & Buying Criteria
- 5.16.1 Key Stakeholders In Buying Process
- 5.16.2 Key Buying Criteria
- 5.17 Impact Of Ai/Gen Ai On Neuromodulation Market
- 5.17.1 Introduction
- 5.17.2 Potential Of Ai
- 5.17.3 Impact Of Ai
- 5.17.4 Key Companies Implementing Ai
- 5.17.5 Future Of Ai
- 5.18 Impact Of 2025 Us Tariff On Neuromodulation Market
- 5.18.1 Introduction
- 5.18.2 Key Tariff Rates
- 5.18.3 Price Impact Analysis
- 5.18.4 Impact On Country/Region
- 5.18.4.1 North America
- 5.18.4.2 Europe
- 5.18.4.3 Asia Pacific
- 5.18.5 Impact On End-use Industries
- 5.18.5.1 Hospitals
- 6 Neuromodulation Market, By Technology
- 6.1 Introduction
- 6.2 Internal Neuromodulation
- 6.2.1 Internal Neuromodulation To Result In Better Treatment
- Results And Lower Healthcare Costs
- 6.3 External Neuromodulation
- 6.3.1 Rising Demand For Non-invasive Solutions For Neurological
- And Pain-related Disorders To Fuel Growth
- 7 Neuromodulation Market, By Stimulation Type
- 7.1 Introduction
- 7.2 Spinal Cord Stimulation
- 7.2.1 Growing Incidence Of Spinal Cord Injuries To Fuel Market Growth
- 7.3 Deep Brain Stimulation
- 7.3.1 Minimally Invasive Deep Brain Stimulation To Deliver Controlled Electrical Impulses And Reduce Side Effects
- 7.4 Sacral Nerve Stimulation
- 7.4.1 Increasing Prevalence Of Chronic Urinary Incontinence Among Elderly Women To Propel Market Growth
- 7.5 Vagus Nerve Stimulation
- 7.5.1 Rising Incidence Of Epilepsy To Drive Adoption Of Next-generation Vagus Nerve Stimulation Therapy
- 7.6 Gastric Nerve Stimulation
- 7.6.1 Increasing Prevalence Of Gastroesophageal Reflux Disease And Gastroparesis To Fuel Market Growth
- 7.7 Transcutaneous Electrical Nerve Stimulation
- 7.7.1 Low Cost And Ease Of Use To Fuel Adoption In Healthcare Sector
- 7.8 Transcranial Magnetic Stimulation
- 7.8.1 Minimal Patient Discomfort Associated With Transcranial Magnetic Stimulation To Support Demand
- 7.9 Respiratory Electrical Stimulation
- 7.9.1 High Treatment Efficacy And Increased Focus On Minimally Invasive Spinal Cord Treatment To Fuel Market Growth
- 7.10 Other Stimulation Types
- 8 Neuromodulation Market, By Application
- 8.1 Introduction
- 8.2 Neuromodulation Market For Spinal Cord Stimulation, By Application
- 8.2.1 Chronic Pain
- 8.2.1.1 High Incidence Of Chronic Pain Among Geriatric Population To Support Market Growth
- 8.2.2 Failed Back Surgery Syndrome
- 8.2.2.1 Increasing Number Of Spinal Surgeries To Aid Market Growth
- 8.2.3 Ischemia
- 8.2.3.1 High Effectiveness Of Neuromodulation To Boost Effectiveness For Ischemia Treatment
- 8.3 Neuromodulation Market For Deep Brain Stimulation, By Application
- 8.3.1 Parkinson’s Disease
- 8.3.1.1 Development Of Advanced Solutions And Increased R&D To Improve Market Growth
- 8.3.2 Tremors
- 8.3.2.1 Increased Prevalence Of Tremors And High Efficacy Of Deep Brain Stimulation To Drive Market
- 8.3.3 Depression
- 8.3.3.1 Ongoing Research And Clinical Studies To Boost Adoption Of Deep Brain Stimulation For Depression Treatment
- 8.3.4 Other Deep Brain Stimulation Applications
- 8.4 Neuromodulation Market For Sacral Nerve Stimulation, By Application
- 8.4.1 Urine Incontinence
- 8.4.1.1 High Incidence Of Urine Incontinence To Offer Growth Opportunities For Market Players
- 8.4.2 Fecal Incontinence
- 8.4.2.1 Reduced Symptom Recurrence With Sacral Nerve Stimulation To Aid Long-term Management Of Fecal Incontinence
- 8.5 Neuromodulation Market For Vagus Nerve Stimulation, By Application
- 8.5.1 Epilepsy
- 8.5.1.1 Low Risk With Device Implantation And Long-lasting Battery Life To Aid Market Growth
- 8.5.2 Other Vagus Nerve Stimulation Applications
- 8.6 Neuromodulation Market For Gastric Electrical Stimulation,
- By Application
- 8.6.1 Gastroparesis
- 8.6.1.1 Reduced Hospitalization Time Associated With Sastroparesis Treatment To Augment Market Growth
- 8.6.2 Obesity
- 8.6.2.1 High Prevalence Of Obesity And Risks Associated With Gastric Bypass To Propel Market Growth
- 8.7 Neuromodulation Market For Transcutaneous Electrical Nerve Stimulation, By Application
- 8.7.1 Treatment-resistant Depression
- 8.7.1.1 High Prevalence Of Chronic And Recurrent Depression To Augment Market Growth
- 8.7.2 Other Transcutaneous Electrical Nerve Stimulation Applications
- 8.8 Neuromodulation Market For Transcranial Magnetic Stimulation,
- By Application
- 8.8.1 Depression
- 8.8.1.1 Repeated Transcranial Magnetic Stimulation To Be Well-tolerated Procedure With Improved Acceptance Among Patients
- 8.8.2 Migraine
- 8.8.2.1 High Prevalence Of Migraines To Support Market Growth
- 8.9 Neuromodulation Market For Respiratory Electrical Stimulation,
- By Application
- 8.9.1 Increasing Incidence Of Spinal Cord Injuries To Ensure Continued Demand For Advanced Treatment Options
- 8.10 Other Applications
- 9 Neuromodulation Market, By End User
- 9.1 Introduction
- 9.2 Hospitals & Ambulatory Surgery Centers
- 9.2.1 Advanced Infrastructure And Ability To Manage Complex Neurological Cases To Propel Market Growth
- 9.3 Clinics & Physiotherapy Centers
- 9.3.1 Need For Focused Expertise And Better Rehabilitation Management To Accelerate Market Expansion
- 9.4 Other End Users
- 10 Neuromodulation Market, By Region
- 10.1 Introduction
- 10.2 North America
- 10.2.1 Macroeconomic Outlook For North America
- 10.2.2 Us
- 10.2.2.1 Us To Dominate North American Neuromodulation Market During Forecast Period
- 10.2.3 Canada
- 10.2.3.1 Increasing Neurological Disorder Rates And Rising Government Funding To Propel Market Growth
- 10.3 Europe
- 10.3.1 Macroeconomic Outlook For Europe
- 10.3.2 Germany
- 10.3.2.1 Advanced Surgical Innovations And Favorable Reimbursement Policies To Drive Market
- 10.3.3 France
- 10.3.3.1 Favorable Healthcare Reforms To Drive Adoption Of Advanced Neuromodulation Techniques
- 10.3.4 Uk
- 10.3.4.1 Increased Public & Private Sector Healthcare Expenditure And Investments To Fuel Market Growth
- 10.3.5 Italy
- 10.3.5.1 Rising Cases Of Dementia And Alzheimer’s Among Geriatric Population To Spur Market Growth
- 10.3.6 Spain
- 10.3.6.1 Favorable Government-led Healthcare Initiatives To Support Market Growth
- 10.3.7 Russia
- 10.3.7.1 Shifting Demographic Landscape And Escalating Neurological Health Needs To Drive Demand
- 10.3.8 Rest Of Europe
- 10.4 Asia Pacific
- 10.4.1 Macroeconomic Outlook For Asia Pacific
- 10.4.2 China
- 10.4.2.1 Government-led Healthcare Reforms And High Prevalence Of Neurological Disorders To Fuel Demand
- 10.4.3 Japan
- 10.4.3.1 Innovative Healthcare Delivery And Advanced Infrastructure Landscape To Augment Market Growth
- 10.4.4 India
- 10.4.4.1 Booming Medical Tourism And Rising Middle Class With Higher Disposable Incomes To Accelerate Market Growth
- 10.4.5 Australia
- 10.4.5.1 Increasing Cases Of Depressive And Post-traumatic Stress Disorders To Propel Market Demand
- 10.4.6 Rest Of Asia Pacific
- 10.5 Latin America
- 10.5.1 Macroeconomic Outlook For Latin America
- 10.5.2 Brazil
- 10.5.2.1 Improvements In Healthcare Infrastructure To Aid Market Growth
- 10.5.3 Mexico
- 10.5.3.1 Expanding Healthcare Awareness And Growing Burden Of Neurological Disorders To Favor Market Growth
- 10.5.4 Rest Of Latin America
- 10.6 Middle East & Africa
- 10.6.1 Improvements In Healthcare Infrastructure And Increased Awareness Of Neurological Care To Drive Market
- 10.6.2 Macroeconomic Outlook For Middle East & Africa
- 11 Competitive Landscape
- 11.1 Introduction
- 11.2 Key Player Strategies/Right To Win
- 11.2.1 Major Strategies Adopted By Key Players In Neuromodulation Market
- 11.3 Revenue Analysis, 2020–2024
- 11.4 Market Share Analysis, 2024
- 11.5 Company Evaluation Matrix: Key Players, 2024
- 11.5.1 Stars
- 11.5.2 Emerging Leaders
- 11.5.3 Pervasive Players
- 11.5.4 Participants
- 11.5.5 Company Footprint: Key Players, 2024
- 11.5.5.1 Company Footprint
- 11.5.5.2 Region Footprint
- 11.5.5.3 Technology Footprint
- 11.5.5.4 Stimulation Type Footprint
- 11.5.5.5 End-user Footprint
- 11.6 Company Evaluation Matrix: Startups/Smes, 2024
- 11.6.1 Progressive Companies
- 11.6.2 Responsive Companies
- 11.6.3 Dynamic Companies
- 11.6.4 Starting Blocks
- 11.6.5 Competitive Benchmarking: Startups/Smes, 2024
- 11.6.5.1 Detailed List Of Key Startups/Smes
- 11.6.5.2 Competitive Benchmarking Of Startups/Smes
- 11.7 Company Valuation & Financial Metrics
- 11.7.1 Company Valuation
- 11.7.2 Financial Metrics
- 11.8 Brand/Product Comparison
- 11.9 Competitive Scenario
- 11.9.1 Product Launches & Approvals
- 11.9.2 Deals
- 12 Company Profiles
- 12.1 Key Players
- 12.1.1 Medtronic
- 12.1.1.1 Business Overview
- 12.1.1.2 Products Offered
- 12.1.1.3 Recent Developments
- 12.1.1.3.1 Product Approvals
- 12.1.1.4 Mnm View
- 12.1.1.4.1 Right To Win
- 12.1.1.4.2 Strategic Choices
- 12.1.1.4.3 Weaknesses & Competitive Threats
- 12.1.2 Boston Scientific Corporation
- 12.1.2.1 Business Overview
- 12.1.2.2 Products Offered
- 12.1.2.3 Recent Developments
- 12.1.2.3.1 Product Approvals
- 12.1.2.3.2 Deals
- 12.1.2.4 Mnm View
- 12.1.2.4.1 Right To Win
- 12.1.2.4.2 Strategic Choices
- 12.1.2.4.3 Weaknesses & Competitive Threats
- 12.1.3 Abbott
- 12.1.3.1 Business Overview
- 12.1.3.2 Products Offered
- 12.1.3.3 Recent Developments
- 12.1.3.3.1 Product Launches And Approvals
- 12.1.3.4 Mnm View
- 12.1.3.4.1 Right To Win
- 12.1.3.4.2 Strategic Choices
- 12.1.3.4.3 Weaknesses & Competitive Threats
- 12.1.4 Livanova Plc
- 12.1.4.1 Business Overview
- 12.1.4.2 Products Offered
- 12.1.4.3 Recent Developments
- 12.1.4.3.1 Product Launches
- 12.1.4.4 Mnm View
- 12.1.4.4.1 Right To Win
- 12.1.4.4.2 Strategic Choices
- 12.1.4.4.3 Weaknesses & Competitive Threats
- 12.1.5 Nevro Corp.
- 12.1.5.1 Business Overview
- 12.1.5.2 Products Offered
- 12.1.5.3 Recent Developments
- 12.1.5.3.1 Product Approvals
- 12.1.5.3.2 Deals
- 12.1.5.4 Mnm View
- 12.1.5.4.1 Right To Win
- 12.1.5.4.2 Strategic Choices
- 12.1.5.4.3 Weaknesses & Competitive Threats
- 12.1.6 Neuropace, Inc.
- 12.1.6.1 Business Overview
- 12.1.6.2 Products Offered
- 12.1.7 Bioventus
- 12.1.7.1 Business Overview
- 12.1.7.2 Products Offered
- 12.1.7.3 Recent Developments
- 12.1.7.3.1 Product Approvals
- 12.1.8 Electrocore, Inc.
- 12.1.8.1 Business Overview
- 12.1.8.2 Products Offered
- 12.1.8.3 Recent Developments
- 12.1.8.3.1 Product Launches
- 12.1.8.3.2 Deals
- 12.1.9 Helius Medical Technologies, Inc.
- 12.1.9.1 Business Overview
- 12.1.9.2 Products Offered
- 12.1.9.3 Recent Developments
- 12.1.9.3.1 Deals
- 12.1.10 Neuronetics
- 12.1.10.1 Business Overview
- 12.1.10.2 Products Offered
- 12.1.10.3 Recent Developments
- 12.1.10.3.1 Product Approvals
- 12.1.10.3.2 Deals
- 12.2 Other Players
- 12.2.1 Neurosigma, Inc.
- 12.2.2 Soterix Medical Inc.
- 12.2.3 Synapse Biomedical Inc.
- 12.2.4 Aleva Neurotherapeutics
- 12.2.5 Theranica Bio-electronics Ltd.
- 12.2.6 Gimer Medical
- 12.2.7 Nalu Medical, Inc.
- 12.2.8 Microtransponder Inc.
- 12.2.9 Magstim
- 12.2.10 Amber Therapeutics
- 12.2.11 Tvns Technologies Gmbh
- 12.2.12 Biowave
- 12.2.13 Biotronik
- 12.2.14 Saluda Medical Pty Ltd.
- 12.2.15 Spr
- 13 Appendix
- 13.1 Discussion Guide
- 13.2 Knowledgestore: Marketsandmarkets’ Subscription Portal
- 13.3 Customization Options
- 13.4 Related Reports
- 13.5 Author Details
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
